The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2019

Filed:

Nov. 24, 2015
Applicant:

Trophea Development Ab, Helsingborg, SE;

Inventors:

Jan Faergemann, Göteburg, SE;

Gudmundur Johannsson, Halmstad, SE;

Claes Ohlsson, Västra Frölunda, SE;

Derek Gregory Batcheller, Brussels, BE;

Jörgen Johnsson, Helsingborg, SE;

Jan Törnell, Västra Frölunda, SE;

Assignee:

TROPHEA DEVELOPMENT AB, Helsingborg, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5685 (2006.01); A61K 8/06 (2006.01); A61Q 19/08 (2006.01); A61Q 19/00 (2006.01); A61P 17/18 (2006.01); A61K 8/365 (2006.01); A61K 8/63 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/192 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 17/08 (2006.01); A61P 17/10 (2006.01); A61P 17/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5685 (2013.01); A61K 8/06 (2013.01); A61K 8/062 (2013.01); A61K 8/365 (2013.01); A61K 8/63 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 31/192 (2013.01); A61K 45/06 (2013.01); A61P 17/00 (2018.01); A61P 17/02 (2018.01); A61P 17/06 (2018.01); A61P 17/08 (2018.01); A61P 17/10 (2018.01); A61P 17/16 (2018.01); A61P 17/18 (2018.01); A61Q 19/00 (2013.01); A61Q 19/08 (2013.01);
Abstract

The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit. This study has for the first time shown that a combination of TRIAC and DHEA could effectively stimulate collagen synthesis in skin pretreated with betamethasone valerate demonstrated by an increase in PINP, and that the combination was more effective than TRIAC or DHEA alone. This combination could be used to effectively treat skin atrophy in corticosteroid induced skin atrophy. It could also be used to treat skin atrophy due to other circumstances such as e. g. sun damaged skin and skin atrophy due to high age. Another interesting application would be to combine TRIAC and DHEA with a potent corticosteroid in order to prevent corticosteroid induced skin atrophy. If this combination still is effective in the treatment of eczema and psoriasis and without the risk of skin atrophy this combination will be a major breakthrough for the use of potent topical corticosteroids.


Find Patent Forward Citations

Loading…